Clinically, dopamine receptor agonists (DAs) (primarily bromocriptine [BRC] and cabergoline [CAB]) are the first-line treatment for the majority of patients with prolactinomas, and they effectively suppress prolactin secretion and shrink tumor volume in most patients 3. This evidence concerns the gene PRL and neoplasm.